Diaceutics (LON:DXRX) Shares Down 0.7% - Here's Why

Key Points

• Shares slipped 0.7% to GBX 144.55 on Thursday with only ~31,072 shares traded, a 78% decline versus average daily volume.
• Analysts remain bullish: Shore Capital raised its price target to GBX 215 and the stock carries a consensus "Buy" rating with an average target of GBX 193.33.
• Mixed fundamentals: market cap £122.33m and a negative PE of -80.31 indicate unprofitability, though liquidity ratios are strong (current 3.96, quick 9.92).

Diaceutics PLC (LON:DXRX - Get Free Report) dropped 0.7% on Thursday . The company traded as low as GBX 144.52 and last traded at GBX 144.55. Approximately 31,072 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 143,706 shares. The stock had previously closed at GBX 145.50.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group boosted their price target on Diaceutics from GBX 180 to GBX 215 and gave the stock a "buy" rating in a report on Thursday, January 15th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, Diaceutics currently has a consensus rating of "Buy" and an average price target of GBX 193.33.

Diaceutics Trading Down 0.7%

The company has a 50-day moving average of GBX 156.03 and a 200 day moving average of GBX 152.45. The company has a debt-to-equity ratio of 3.05, a current ratio of 3.96 and a quick ratio of 9.92. The company has a market cap of £122.33 million, a PE ratio of -80.31 and a beta of 0.58.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.